MiR-519d Targets HER3 and Can Be Used As a Potential Serum Biomarker for Non-small Cell Lung Cancer

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2020 Mar 15

PMID 32170048

Citations 7

Authors

Aili Wang

Hongxia Zhang

Jinxiang Wang

Shuming Zhang

Zhenyang Xu

Affiliations

Soon will be listed here.

Abstract

Development of specific serum biomarkers is essential to improve diagnosis and prognosis of non-small cell lung cancer (NSCLC). Here, we show that serum and tissue levels of miR-519d are significantly decreased in NSCLC patients. The low expression of miR-519d is associated with lymph node metastases, clinical stage, and a poor prognosis in NSCLC patients. In addition, ROC analysis demonstrated that the serum miR-519d levels can distinguish NSCLC patients from healthy controls. MiR-519d inhibits proliferation, migration, and invasion by lung cancer cells, indicating that it may function as a tumor suppressor in lung cancer. Furthermore, our data demonstrate that HER3 is a target gene of miR-519d in lung cancer cells, and show that by targeting HER3, miR-519d inhibits the PI3K/Akt pathway. These findings demonstrate that the miR-519d levels are decreased in serum and tumor tissues of NSCLC patients, and indicate that miR-519d regulates NSCLC progression by targeting HER3. MiR-519d could potentially serve as a novel serum biomarker for NSCLC.

Citing Articles

MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment.

Nucera F, Ruggeri P, Claudia Spagnolo C, Santarpia M, Ieni A, Monaco F Int J Mol Sci. 2024; 25(12).

PMID: 38928392 PMC: 11203619. DOI: 10.3390/ijms25126685.

Advances in the role of microRNAs associated with the PI3K/AKT signaling pathway in lung cancer.

Wang Y, Zhang T, He X Front Oncol. 2024; 13:1279822.

PMID: 38169723 PMC: 10758458. DOI: 10.3389/fonc.2023.1279822.

Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.

Garbo E, Del Rio B, Ferrari G, Cani M, Napoli V, Bertaglia V Cancers (Basel). 2023; 15(19).

PMID: 37835468 PMC: 10571819. DOI: 10.3390/cancers15194774.

Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients.

Raczkowska J, Bielska A, Kretowski A, Niemira M Front Oncol. 2023; 13:1209299.

PMID: 37546401 PMC: 10401434. DOI: 10.3389/fonc.2023.1209299.

Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC.

Li Y, Ye J, Xu S, Wang J Discov Oncol. 2023; 14(1):142.

PMID: 37526759 PMC: 10393935. DOI: 10.1007/s12672-023-00686-3.

References

Yu X, Ghamande S, Liu H, Xue L, Zhao S, Tan W . Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2 Breast Cancer. Mol Ther Nucleic Acids. 2018; 10:317-330. PMC: 5862534. DOI: 10.1016/j.omtn.2017.12.015. View

Yan C, Lu Y, Tang S, Fan W . MiR-519d inhibits prostate cancer cell proliferation, cycle and invasion via targeting NRBP1. Eur Rev Med Pharmacol Sci. 2018; 22(10):2985-2990. DOI: 10.26355/eurrev_201805_15054. View

Tao X, Zeng L, Wang H, Liu H . LncRNA MEG3 ameliorates respiratory syncytial virus infection by suppressing TLR4 signaling. Mol Med Rep. 2017; 17(3):4138-4144. DOI: 10.3892/mmr.2017.8303. View

Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli G, Rossi E . HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer. 2005; 93(12):1334-40. PMC: 2361531. DOI: 10.1038/sj.bjc.6602865. View

Karachaliou N, Lazzari C, Verlicchi A, Sosa A, Rosell R . HER3 as a Therapeutic Target in Cancer. BioDrugs. 2016; 31(1):63-73. DOI: 10.1007/s40259-016-0205-2. View

Jiang L, Shi S, Shi Q, Zhang H, Xia Y, Zhong T . MicroRNA-519d-3p Inhibits Proliferation and Promotes Apoptosis by Targeting HIF-2α in Cervical Cancer Under Hypoxic Conditions. Oncol Res. 2018; 26(7):1055-1062. PMC: 7844701. DOI: 10.3727/096504018X15152056890500. View

Pastuszak-Lewandoska D, Kordiak J, Czarnecka K, Migdalska-Sek M, Nawrot E, Domanska-Senderowska D . Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d, in relation to MMP-2 expression level in non-small cell lung cancer patients: a pilot study. Med Oncol. 2016; 33(8):96. DOI: 10.1007/s12032-016-0815-z. View

Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T . Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab. Oncology. 2017; 93(1):51-61. DOI: 10.1159/000468521. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

10.

Li Y, Shao J, Zhang S, Xing G, Liu H . miR-519d-3p Inhibits Cell Proliferation and Invasion of Gastric Cancer by Downregulating B-Cell Lymphoma 6. Cytogenet Genome Res. 2018; 154(1):12-19. PMC: 5969071. DOI: 10.1159/000487372. View

11.

Ye X, Lv H . MicroRNA-519d-3p inhibits cell proliferation and migration by targeting TROAP in colorectal cancer. Biomed Pharmacother. 2018; 105:879-886. DOI: 10.1016/j.biopha.2018.04.114. View

12.

Grimolizzi F, Monaco F, Leoni F, Bracci M, Staffolani S, Bersaglieri C . Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression. Sci Rep. 2017; 7(1):15277. PMC: 5681649. DOI: 10.1038/s41598-017-15475-6. View

13.

Cao G, Chen K, Chen B, Xiong M . Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. BMC Cancer. 2017; 17(1):841. PMC: 5727869. DOI: 10.1186/s12885-017-3851-y. View

14.

Yonesaka K, Kudo K, Nishida S, Takahama T, Iwasa T, Yoshida T . The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget. 2015; 6(32):33602-11. PMC: 4741788. DOI: 10.18632/oncotarget.5286. View

15.

Fang W, Guo J, Cao Y, Wang S, Pang C, Li M . MicroRNA-20a-5p contributes to hepatic glycogen synthesis through targeting p63 to regulate p53 and PTEN expression. J Cell Mol Med. 2016; 20(8):1467-80. PMC: 4956936. DOI: 10.1111/jcmm.12835. View

16.

Wang K, Dong L, Fang Q, Xia H, Hou X . Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer. Cancer Biomark. 2017; 20(3):283-288. DOI: 10.3233/CBM-170124. View

17.

Sithanandam G, Fornwald L, Fields J, Anderson L . Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene. 2005; 24(11):1847-59. DOI: 10.1038/sj.onc.1208381. View

18.

Wang S, Li Y, Jiang Y, Li R . Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2017; 21(18):4092-4097. View

19.

Dejima H, Iinuma H, Kanaoka R, Matsutani N, Kawamura M . Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncol Lett. 2017; 13(3):1256-1263. PMC: 5403401. DOI: 10.3892/ol.2017.5569. View

20.

Bai Y, Lu C, Zhang G, Hou Y, Guo Y, Zhou H . Overexpression of miR-519d in lung adenocarcinoma inhibits cell proliferation and invasion via the association of eIF4H. Tumour Biol. 2017; 39(3):1010428317694566. DOI: 10.1177/1010428317694566. View